Shares of Korro Bio jumped 10.4% to $12.20 on June 18 after Jones Trading upgraded the stock from Hold to Buy, slapping a $23.00 price target that implies roughly 88% upside from here. The move caps a volatile stretch for a company still rebuilding credibility after a painful clinical failure — and forces investors to ask whether the science has truly turned a corner or whether Wall Street is pricing in hope.
A Failed Drug, Then a Pivot — Now Analysts Are Believers Again
Korro amended its agreement with Novo Nordisk after the failed Phase 1/2a REWRITE trial , a setback that crushed the stock in late 2025. The company has since pivoted to a new lead drug for hyperammonemia — dangerously high ammonia in the blood — targeting urea cycle disorders and hepatic encephalopathy, each representing over $1 billion in market opportunity.
The Jones Trading upgrade follows Q1 2026 results, with three analysts revising earnings upward — a signal that confidence in the new direction is broadening.
The Lab Numbers Look Strong, but Patients Haven't Taken the Drug Yet
Korro plans to present preclinical data showing its new lung-disease drug candidate achieved greater than 90% RNA editing in living animals, compared with roughly 60% for its prior candidate.
In mice, the drug nearly eliminated toxic protein production, reducing it by approximately 95%. Impressive in a lab — but no human has taken the medicine yet. A regulatory submission for the first human trial is expected in the second half of 2026.
$85 Million in Fresh Cash Buys Time, Not Certainty
Korro raised $85 million in an oversubscribed private placement, extending its cash runway into the second half of 2028 — enough to fund early clinical readouts across multiple programs. That's essential for a company with zero revenue. The stock has rebounded 61% year-to-date , yet remains far below its prior peaks.
Wall Street Is Clustering Around Bullish Targets — With One Big Caveat
Jones Trading notes Korro has a "fast-follower advantage" as rivals Wave Life Sciences and Beam Therapeutics define the regulatory path for genetic medicines in this disease area. But analysts acknowledge significant clinical de-risking remains. H.C. Wainwright's $15 target and Jones's $23 target bracket the optimism, but both hinge on human data that won't arrive for months.